Who are liraglutide combined with orlistat's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/liraglutide-combined-with-orlistat.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

liraglutide combined with orlistat — Competitive Intelligence Brief

liraglutide combined with orlistat (liraglutide combined with orlistat) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist combined with pancreatic lipase inhibitor. Area: Endocrinology / Obesity.

marketed GLP-1 receptor agonist combined with pancreatic lipase inhibitor GLP-1 receptor (liraglutide); pancreatic and gastric lipases (orlistat) Endocrinology / Obesity Small molecule Live · refreshed every 30 min

Target snapshot

liraglutide combined with orlistat (liraglutide combined with orlistat) — The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Liraglutide stimulates GLP-1 receptors to increase insulin secretion and reduce appetite, while orlistat inhibits pancreatic lipase to reduce dietary fat absorption.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
liraglutide combined with orlistat TARGET	liraglutide combined with orlistat	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed	GLP-1 receptor agonist combined with pancreatic lipase inhibitor	GLP-1 receptor (liraglutide); pancreatic and gastric lipases (orlistat)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist combined with pancreatic lipase inhibitor class)

The Fourth Affiliated Hospital of Zhejiang University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). liraglutide combined with orlistat — Competitive Intelligence Brief. https://druglandscape.com/ci/liraglutide-combined-with-orlistat. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab